Advertisement

Phytochemistry Reviews

, Volume 14, Issue 3, pp 429–441 | Cite as

Current status of CPT and its analogues in the treatment of malignancies

  • Guohua Hu
  • David Zekria
  • Xun Cai
  • Xiaoling Ni
Article

Abstract

Camptothecin (CPT) is a kind of terpene indole alkaloid which was firstly isolated from native Chinese happy tree Camptotheca acuminata and owns a unique anti-tumor mechanism by inhibiting Topo I. Being approved by FDA, the camptothecin derivatives, irinotecan and topotecan, are extensively used for the treatment of various cancers throughout the world. In the past decades, pharmacology of CPT and its analogues has been well documented. This review will focus on different human malignancies with demonstrated clinical efficacy of CPT analogues.

Keywords

Analogues Camptothecin Chemotherapy Malignancies 

Notes

Acknowledgments

The authors are grateful for financial sponsored by the Shanghai Committee of Science and Technology, China (13140902402).

Conflict of interest

The authors confirm that this article content has no conflicts of interest.

References

  1. Abou-Alfa GK, Letourneau R, Harker G et al (2006) Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24:4441–4447PubMedGoogle Scholar
  2. Ajani JA, Takimoto C, Becerra CR et al (2005) A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs 23:479–484PubMedGoogle Scholar
  3. Arakawa Y, Saito S, Yamada H et al (2009) Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-X(L) and promotes apoptosis of MCF-7 breast cancer cells. Apoptosis 14:1076–1085PubMedGoogle Scholar
  4. Baka S, Agelaki S, Kotsakis A et al (2010) Phase III study comparing sequential versus alternate administration of cisplatin–etoposide and topotecan as first-line treatment in small cell lung cancer. Anticancer Res 30:3031–3038PubMedGoogle Scholar
  5. Bastos BR, Hatoum GF, Walker GR et al (2010) Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol 5:533–539PubMedGoogle Scholar
  6. Bodurka DC, Levenback C, Wolf JK et al (2003) Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 21:291–297PubMedGoogle Scholar
  7. Bolis G, Scarfone G, Raspagliesi F et al (2010) Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III–IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer 46:2905–2912PubMedGoogle Scholar
  8. Brave M, Dagher R, Farrell A et al (2006) Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park) 20:1401–1404Google Scholar
  9. Bryce AH, Mattar B, Hillman SL et al (2010) Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: a North Central Cancer Treatment Group Study. Am J Clin Oncol 33:353–357PubMedGoogle Scholar
  10. Burris HA 3rd, Rivkin S, Reynolds R et al (2005) Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 10:183–190PubMedGoogle Scholar
  11. Chang H, Kim SH, Cho BC et al (2012) Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer. Anticancer Res 32:3515–3521PubMedGoogle Scholar
  12. Charpidou A, Tsagouli S, Tsimpoukis S et al (2010) Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study. Anticancer Drugs 21:651–655PubMedGoogle Scholar
  13. Chen G, Huynh M, Fehrenbacher L et al (2009) Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol 27:1401–1404PubMedCentralPubMedGoogle Scholar
  14. Chitapanarux I, Tonusin A, Sukthomya V et al (2003) Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol 89:402–407PubMedGoogle Scholar
  15. Choi CH, Lee YY, Song TJ et al (2011) Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. Cancer 117:2104–2111PubMedGoogle Scholar
  16. Cichorek M, Kozlowska K, Bryl E (2007) The activity of caspases in spontaneous and camptothecin-induced death of melanotic and amelanotic melanoma cell. Cancer Biol Ther 6:346–353PubMedGoogle Scholar
  17. Cirpanli Y, Allard E, Passirani C et al (2011) Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int J Pharm 403:201–206PubMedGoogle Scholar
  18. Conti JA, Kemeny NE, Saltz LB et al (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709–715PubMedGoogle Scholar
  19. Cormio G, Loizzi V, Gissi F et al (2011) Long-term topotecan therapy in recurrent or persistent ovarian cancer. Eur J Gynaecol Oncol 32:153–155PubMedGoogle Scholar
  20. Coronel J, Cetina L, Candelaria M et al (2009) Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. Med Oncol 26:210–214PubMedGoogle Scholar
  21. Di Francesco AM, Riccardi A, Barone G et al (2005) The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. Biochem Pharmacol 70:1125–1136PubMedGoogle Scholar
  22. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047PubMedGoogle Scholar
  23. Eckardt JR, von Pawel J, Pujol JL et al (2007) Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086–2092PubMedGoogle Scholar
  24. El-Galley R, Keane TE, Sun C (2003) Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft. Urol Oncol 21:49–57PubMedGoogle Scholar
  25. Farhat FS (2007) A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 24:137–146PubMedGoogle Scholar
  26. Fink TH, Huber RM, Heigener DF et al (2012) Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol 7:1432–1439PubMedGoogle Scholar
  27. Fujii T, Kunikane H, Okamoto H et al (2009) A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510. Jpn J Clin Oncol 39:784–790PubMedGoogle Scholar
  28. Fukuda M, Nakamura Y, Kinoshita A et al (2012) Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer. Cancer Chemother Pharmacol 70:645–651PubMedGoogle Scholar
  29. Ge XH, Lin Q, Ren XC et al (2013) Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer. Radiat Oncol 8:238PubMedCentralPubMedGoogle Scholar
  30. Gonzalez EE, Villanueva N, Fra J et al (2011) Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. Invest New Drugs 29:1459–1464PubMedGoogle Scholar
  31. Hariri G, Edwards AD, Merrill TB et al (2014) Sequential targeted delivery of paclitaxel and camptothecin using a cross-linked “nanosponge” network for lung cancer chemotherapy. Mol Pharm 11:265–275PubMedGoogle Scholar
  32. Heinemann V, Hoff PM (2010) Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. Oncology 79:118–128PubMedGoogle Scholar
  33. Hiruma R, Kamide T, Anzai N et al (2008) Combined irinotecan (CPT-11) and nedaplatin (254-S) therapy for advanced and/or recurrent cervical cancer. Gan To Kagaku Ryoho 35:607–610PubMedGoogle Scholar
  34. Hong J, Jung M, Kim YJ et al (2012) Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol 69:215–220PubMedGoogle Scholar
  35. Horn L, Zhao Z, Sandler A et al (2011) A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. Clin Lung Cancer 12:161–165PubMedGoogle Scholar
  36. Hoskins P, Vergote I, Cervantes A et al (2010) Advanced ovarian cancer: phase III randomized study of sequential cisplatin–topotecan and carboplatin–paclitaxel vs carboplatin–paclitaxel. J Natl Cancer Inst 102:1547–1556PubMedGoogle Scholar
  37. Hu Z, Guo X, Yu Q et al (2009) Down-regulation of adenine nucleotide translocase 3 and its role in camptothecin-induced apoptosis in human hepatoma QGY7703 cells. FEBS Lett 583:383–388PubMedGoogle Scholar
  38. Hwang JH, Yoo HJ, Lim MC et al (2012) Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer. Anticancer Drugs 23:321–325PubMedGoogle Scholar
  39. James E, Waldron-Lynch MG, Saif MW (2009) Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs 20:634–638PubMedGoogle Scholar
  40. Jemal A, Center MM, DeSantis C et al (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev 19:1893–1907Google Scholar
  41. Jeong J, Cho BC, Sohn JH et al (2010) Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. Lung Cancer 70:77–81PubMedGoogle Scholar
  42. Kim HG, Lee GW, Kang JH et al (2008) Combination chemotherapy with irinotecan and cisplatin in elderly patients (> or =65 years) with extensive-disease small-cell lung cancer. Lung Cancer 61:220–226PubMedGoogle Scholar
  43. Kim YY, Park CK, Kim SK et al (2009) CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines. Oncol Rep 21:1413–1419PubMedGoogle Scholar
  44. Kim HS, Park NH, Kang S et al (2010a) Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. J Obstet Gynaecol Res 36:86–93PubMedGoogle Scholar
  45. Kim SJ, Kim JS, Kim SC et al (2010b) A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer. Lung Cancer 68:446–449PubMedGoogle Scholar
  46. Kim YM, Lee SW, Kim DY et al (2010c) The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J Chemother 22:197–200PubMedGoogle Scholar
  47. Kim YS, Park SH, Kyung SY et al (2011) Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer. Med Oncol 28:342–350PubMedGoogle Scholar
  48. Kim CY, Lee SJ, Kim SK et al (2012) Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model. J Clin Neurosci 19:301–305PubMedGoogle Scholar
  49. Kim HS, Kim JH, Kim B et al (2013) Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 71:1591–1597PubMedGoogle Scholar
  50. Kraut EH, Balcerzak SP, Young D et al (2000) A phase II study of 9-aminocamptothecin in patients with refractory breast cancer. Cancer Invest 18:28–31PubMedGoogle Scholar
  51. Kurtzberg LS, Roth S, Krumbholz R et al (2011) Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res 17:2777–2787PubMedGoogle Scholar
  52. Lally BE, Urbanic JJ, Blackstock AW et al (2007) Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 12:1096–1104PubMedGoogle Scholar
  53. Lara PN Jr, Natale R, Crowley J et al (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530–2535PubMedCentralPubMedGoogle Scholar
  54. Lee DH, Kim SW, Suh C et al (2008a) Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 19:123–127PubMedGoogle Scholar
  55. Lee HP, Seo SS, Ryu SY et al (2008b) Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol 109:359–363PubMedGoogle Scholar
  56. Lee BS, Nalla AK, Stock IR et al (2010a) Oxidative stimuli-responsive nanoprodrug of camptothecin kills glioblastoma cells. Bioorg Med Chem Lett 20:5262–5268PubMedGoogle Scholar
  57. Lee DH, Kim SW, Suh C et al (2010b) Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer. Cancer 116:132–136PubMedGoogle Scholar
  58. Lee YY, Lee JW, Park HS et al (2010c) Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer. Gynecol Oncol 119:87–91PubMedGoogle Scholar
  59. Li C, Huang XE, Li Y (2011) Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev 12:487–490PubMedGoogle Scholar
  60. Li Z, Li X, Cao Z et al (2012) Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: efficient suppression of growth of multiple myeloma in a murine model. Oncol Rep 27:1035–1040PubMedCentralPubMedGoogle Scholar
  61. Lim S, Cho BC, Jung JY et al (2013) Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. Lung Cancer 80:313–318PubMedGoogle Scholar
  62. Liu W, Zhu YS, Guo M et al (2007) Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia. Leuk Res 31:1565–1574PubMedGoogle Scholar
  63. Liu S, Yuan Y, Okumura Y et al (2010a) Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth. Biochem Biophys Res Commun 394:297–302PubMedGoogle Scholar
  64. Liu XP, Zhou ST, Li XY et al (2010b) Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model. J Exp Clin Cancer Res 29:76PubMedCentralPubMedGoogle Scholar
  65. Long HJ 3rd, Bundy BN, Grendys EC et al (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:4626–4633PubMedGoogle Scholar
  66. Lorusso D, Mainenti S, Pietragalla A et al (2011) Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer. Oncology 80:390–394PubMedGoogle Scholar
  67. Machida S, Ohwada M, Fujiwara H et al (2003) Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. Oncology 65:102–107PubMedGoogle Scholar
  68. Matsumoto K, Katsumata N, Yamanaka Y et al (2006) The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol 100:412–416PubMedGoogle Scholar
  69. McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6PubMedGoogle Scholar
  70. Minelli R, Cavalli R, Ellis L et al (2012) Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. Eur J Pharm Sci 47:686–694PubMedGoogle Scholar
  71. Misumi Y, Nishio M, Takahashi T et al (2014) A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer. Jpn J Clin Oncol 44:116–121PubMedGoogle Scholar
  72. Murata Y, Hirose T, Yamaoka T et al (2011) Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer. Eur J Cancer 47:1336–1342PubMedGoogle Scholar
  73. Nam EJ, Kim JW, Kim JH et al (2010) Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer. Am J Clin Oncol 33:233–237PubMedGoogle Scholar
  74. Niitsu N, Iijima K, Chizuka A (2001) Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin’s lymphoma: a pilot study. Ann Hematol 80:411–416PubMedGoogle Scholar
  75. Nishio S, Sugiyama T, Shouji T et al (2007) Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer. Gynecol Oncol 106:342–347PubMedGoogle Scholar
  76. Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91PubMedGoogle Scholar
  77. Noro R, Yoshimura A, Yamamoto K et al (2013) Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer. Anticancer Res 33:1117–1123PubMedGoogle Scholar
  78. Numbenjapon T, Wang J, Colcher D et al (2009) Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res 15:4365–4373PubMedCentralPubMedGoogle Scholar
  79. O’Brien ME, Ciuleanu TE, Tsekov H et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan inpatients with relapsed small-cell lung cancer. J Clin Oncol 24:5441–5447PubMedGoogle Scholar
  80. Ohara T, Kobayashi Y, Yoshida A et al (2013) Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer. Int J Clin Oncol 18:1102–1106PubMedGoogle Scholar
  81. Ohe M, Oshita F, Kenmotsu Y et al (2012) Nedaplatin and irinotecan for patients with recurrent small cell lung cancer. J Exp Ther Oncol 10:65–69PubMedGoogle Scholar
  82. Okishio K, Mio T, Kawahara M et al (2012) A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02. Jpn J Clin Oncol 42:387–393PubMedGoogle Scholar
  83. Oshita F, Sugiura M, Murakami S et al (2013) Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer. Cancer Chemother Pharmacol 71:345–350PubMedGoogle Scholar
  84. Papadimitriou CA, Papakostas P, Karina M et al (2011) A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med 9:10PubMedCentralPubMedGoogle Scholar
  85. Parra E, Ferreira J (2010) The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines. Oncol Rep 23:1159–1165PubMedGoogle Scholar
  86. Polyzos A, Kosmas C, Toufexi H et al (2005) Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res 25:3559–3564PubMedGoogle Scholar
  87. Pratesi G, De Cesare M, Carenini N et al (2002) Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res 8:3904–3909PubMedGoogle Scholar
  88. Qi WX, Shen Z, Lin F et al (2013) Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials. Int J Cancer 132:E66–E73PubMedGoogle Scholar
  89. Quintas-Cardama A, Kantarjian H, O’Brien S et al (2006) Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 107:1525–1529PubMedGoogle Scholar
  90. Ramasubbaiah R, Perkins SM, Schilder J et al (2011) Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 123:499–504PubMedGoogle Scholar
  91. Raspagliesi F, Ditto A, Selvaggi L et al (2010) A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer. Int J Gynecol Cancer 20:1569–1575PubMedGoogle Scholar
  92. Reinicke KE, Kuffel MJ, Goetz MP et al (2010) Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells. Cancer Chemother Pharmacol 66:575–583PubMedCentralPubMedGoogle Scholar
  93. Ren Y, Li Y, Liu J (2011) A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer. Int J Gynecol Cancer 21:685–689PubMedGoogle Scholar
  94. Rhee CK, Lee SH, Kim JS et al (2011) A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer. Lung Cancer 72:64–67PubMedGoogle Scholar
  95. Rougier P, Bugat R, Douillard JY et al (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251–260PubMedGoogle Scholar
  96. Rudolf E, Rudolf K, Cervinka M (2011) Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells. Apoptosis 16:1165–1176PubMedGoogle Scholar
  97. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914PubMedGoogle Scholar
  98. Saotome T, Takagi T, Sakai C et al (2000) Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin’s lymphoma. Ann Oncol 11:115–116PubMedGoogle Scholar
  99. Schluep T, Hwang J, Cheng J et al (2006) Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 12:1606–1614PubMedGoogle Scholar
  100. Schmittel A, Sebastian M, Fischer von Weikersthal L et al (2011) A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 22:1798–1804PubMedGoogle Scholar
  101. Scott LC, Yao JC, Benson AB 3rd et al (2009) A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol 63:363–370PubMedGoogle Scholar
  102. Sehouli J, Stengel D, Harter P et al (2011) Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 29:242–248PubMedGoogle Scholar
  103. Seung SK, Ross HJ (2009) Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer. Int J Radiat Oncol Biol Phys 73:802–809PubMedGoogle Scholar
  104. Shimada Y, Yoshino M, Wakui A et al (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11:909–913PubMedGoogle Scholar
  105. Shoji T, Takatori E, Hatayama S et al (2010) Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer. Oncol Lett 1:515–519PubMedCentralPubMedGoogle Scholar
  106. Shoji T, Takatori E, Omi H, Kumagai S et al (2011) Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study). Int J Gynecol Cancer 21:44–50PubMedGoogle Scholar
  107. Spigel DR, Greco FA, Zubkus JD et al (2009) Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 4:1555–1560PubMedGoogle Scholar
  108. Spigel DR, Hainsworth JD, Gandhi JG et al (2010) A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer. J Thorac Oncol 5:862–866PubMedGoogle Scholar
  109. Stein SM, Tiersten A, Hochster HS et al (2013) A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. Int J Gynecol Cancer 23:1577–1582PubMedGoogle Scholar
  110. Sugiyama T, Yakushiji M, Nishida T et al (1998) Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 128:211–218PubMedGoogle Scholar
  111. Sugiyama T, Nishida T, Kumagai S et al (1999) Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer 81:95–98PubMedCentralPubMedGoogle Scholar
  112. Sugiyama T, Yakushiji M, Noda K et al (2000) Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58:31–37PubMedGoogle Scholar
  113. Sugiyama T, Yakushiji M, Kamura T et al (2002) Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology 63:16–22PubMedGoogle Scholar
  114. Suntornpong N, Pattaranutaporn P, Chanslip Y et al (2003) Concurrent radiation therapy and irinotecan in stage IIIB cervical cancer. J Med Assoc Thai 86:430–435PubMedGoogle Scholar
  115. Suprasert P, Charoenkwan K, Cheewakriangkrai C (2010) Outcomes of advanced and recurrent cervical cancer treated with cisplatin and generic topotecan: retrospective analysis in a tertiary care hospital in Thailand. J Gynecol Oncol 21:237–240PubMedCentralPubMedGoogle Scholar
  116. Suzuki H, Hirashima T, Kobayashi M et al (2011) Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease. J Chemother 23:367–370PubMedGoogle Scholar
  117. Takeda K, Negoro S, Tanaka M et al (2011) A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. Jpn J Clin Oncol 41:25–31PubMedGoogle Scholar
  118. Tan C, Cai LQ, Wu W et al (2009) NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. Cancer Chemother Pharmacol 63:303–312PubMedCentralPubMedGoogle Scholar
  119. Tsuda H, Hashiguchi Y, Nishimura S et al (2004) Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 91:1032–1037PubMedCentralPubMedGoogle Scholar
  120. Ulivi P, Zoli W, Fabbri F et al (2005) Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models. Neoplasia 7:152–161PubMedCentralPubMedGoogle Scholar
  121. Ushijima K, Kamura T, Tamura K et al (2013) Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study. Int J Clin Oncol 18:126–131PubMedGoogle Scholar
  122. Van Cutsem E, Labianca R, Bodoky G et al (2009) Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117–3125PubMedGoogle Scholar
  123. von Pawel J, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667Google Scholar
  124. Wahba HA, Halim AA, El-Hadaad HA (2012) Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer. Med Oncol 29:199–204PubMedGoogle Scholar
  125. Weiss GJ, Chao J, Neidhart JD et al (2013) First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 31:986–1000PubMedCentralPubMedGoogle Scholar
  126. Xenidis N, Kotsakis A, Kalykaki A et al (2010) Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: a multicenter phase II study. Lung Cancer 68:450–454PubMedGoogle Scholar
  127. Xiong Y, Liang LZ, Cao LP et al (2011) Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol 123:99–104PubMedGoogle Scholar
  128. Yahagi N, Kobayashi Y, Ohara T et al (2009) Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer. Gan To Kagaku Ryoho 36:2583–2586PubMedGoogle Scholar
  129. Yoshimura A, Noro R, Miyanaga A et al (2012) Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer. Anticancer Res 32:4473–4478PubMedGoogle Scholar
  130. Zarogoulidis K, Mylonaki E, Kakavelas P et al (2009) Topotecan-carboplatin–etoposide combination as 1st line treatment in patients with small cell lung cancer. Lung Cancer 66:226–230PubMedGoogle Scholar
  131. Zatloukal P, Cardenal F, Szczesna A et al (2010) A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 21:1810–1816PubMedGoogle Scholar
  132. Zhang X, Gan Y, Gan L et al (2008) PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer. J Pharm Pharmacol 60:1077–1087PubMedGoogle Scholar
  133. Zhang H, Jia L, Xu Y et al (2012) Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials. J Chemother 24:67–73PubMedGoogle Scholar
  134. Zhang H, Wang X, Dai W et al (2014) Pharmacokinetics and treatment efficacy of camptothecin nanocrystals on lung metastasis. Mol Pharm 11:226–233PubMedGoogle Scholar
  135. Zhou L, Li X, Chen X et al (2010) In vivo antitumor and antimetastatic activities of camptothecin encapsulated with N-trimethyl chitosan in a preclinical mouse model of liver cancer. Cancer Lett 297:56–64PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.Department of General Surgery, Zhongshan HospitalFudan UniversityShanghaiChina
  2. 2.Shanghai Institute of Hematology and State Key Laboratory of Medical Genomics, Rui-jin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations